PCL2, a novel tumor suppressor in breast cancer

• 来源期刊: 科学通报（英文版）
• 年，卷（期）: 2018,（10）
• 页码范围: 597-598
• 页数: 2页
• 语种: 英文

摘要

Polycomb group (PcG) proteins were originally identified as suppressors of the homeotic genes in Drosophila [1], controlling segment identity during embryonic development. Then PcG proteins were found to participate in the regulation of various biologic processes, including cell cycle, apoptosis and tumor development [2]. It is commonly accepted that the PcG proteins form two major evolutionarily conserved Polycomb Repressive Complexes (PRCs). The Polycomb Repressive Complexes 1 (PRC1) is mainly composed with BMI1, MEL18, RING1, and CBX, which could catalyze monoubiquitination of H2AK119. PRC2 mainly contains EZH2, SUZ12, and EED, which is responsible for catalyzing H3K27me3 [3]. Histone H3 lysine 27 trimethylation (H3K27me3) is a marker for gene silencing, and the enzymatic activity of PRC2 made it significant in various processes, such as stem cell renewal, differentiation, and cancer progression.